secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001213900-25-116971
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERO Therapeutics enters new equity line for up to $14.6M from Keystone Capital
-------------------------------------------------------------------------------

- Company entered a new Common Stock Purchase Agreement with Keystone Capital for up to $14,591,939 of common stock.
- Prior agreements (Feb 2024, Nov 2024, July 2025) raised ~$10.4M total: ~$4.4M (Feb), ~$3.1M (Nov), ~$2.9M (July).
- Minimum stock price for purchases set at $0.02; single fixed purchase limited to 10,000 shares or $100,000.
- Investor's beneficial ownership capped at 4.99% of outstanding shares; registration rights granted.
- Agreement is a continuation of the existing equity line program; no additional commitment shares required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025116971/0001213900-25-116971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025116971/ea0267798-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-116971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer